Severe regimen-related toxicity often complicates second transplant procedures performed in patients with hematological malignancies that have relapsed after an initial hematopoietic stem cell (HSC) transplant. Therefore, we studied the safety and efficacy of a reduced-intensity fludarabine and melphalan based conditioning regimen in 11 patients who had relapsed following an autologous (n = 7) or allogeneic (n = 4) HSC transplant. All patients received allogeneic peripheral blood HSC from either an HLA-identical (n = 7) or an HLA-mismatched (n = 4) relative. Diagnoses included AML (n = 9), ALL (n = 1), or Hodgkin's disease (n = 1). Only one patient was in complete remission at the time of second transplant. The median interval between first transplant and relapse was 163 days (range 58-1885). Recipients of HLA-mismatched transplants received antithymocyte globulin in addition to fludarabine and melphalan as part of the conditioning regimen. All 11 patients received acute GVHD prophylaxis consisting of tacrolimus and methotrexate. Ten of 11 patients achieved hematopoietic engraftment with a median time to absolute neutrophil count Ͼ0.5 × 10 9 /l and to platelet count of Ͼ20 × 10 9 /l of 14 and 19 days, respectively. All engrafting patients achieved 100% donor chimerism on initial analysis, except for one with persistent leukemia at day +19. Two patients experienced grade 3 regimen-related toxicity, manifesting as acute renal failure. Acute GVHD grades 2-4 occurred in two recipients and chronic GVHD in four. The 100-day mortality from all causes was 36%. Ten of 11 patients (91%) died a median of 140 days (range 9-996) after the second transplant. The causes of death included relapse (n = 5), sepsis (n = 4), and idiopathic pneumonia syndrome (n = 1). One patient with AML survives in remission at 880 days post-transplant. We conclude that fludarabine-and melphalan-based conditioning promotes full donor chimerism, even following Hematopoietic stem cell (HSC) transplantation has improved the likelihood of disease-free survival for many patients with hematological disorders. Nevertheless, relapse remains the major cause of treatment failure following HSC transplantation performed in patients with advanced hematological malignancies.
Hematopoietic stem cell (HSC) transplantation has improved the likelihood of disease-free survival for many patients with hematological disorders. Nevertheless, relapse remains the major cause of treatment failure following HSC transplantation performed in patients with advanced hematological malignancies. 1, 2 The prospects for patients relapsing after an HSC transplant are limited. Donor leukocyte infusion (DLI) has been demonstrated to be effective in patients with chronic myelogenous leukemia (CML), but has met with limited success in highly proliferative malignancies, such as acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL). 3, 4 Second HSC transplants using allogeneic donors are often attempted, but are fraught with complications. Regimen-related toxicity is usually prohibitive and outcomes are adversely affected by high rates of infection and graft-versus-host disease (GVHD). 2, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Moreover, relapse is common following a second HSC transplant, particularly for patients not in remission at the time of transplantation. Outcomes are particularly poor for patients relapsing within a year of the first transplant procedure. [6] [7] [8] [9] [10] 15 Due to the severe toxicity associated with second allogeneic HSC transplants following standard myeloablative conditioning, we studied a lower intensity regimen in this setting. We chose to evaluate a regimen containing fludarabine and melphalan based on encouraging data preliminarily reported by another group. 16, 17 The goals of this study were to evaluate the safety and efficacy of fludarabine-and melphalan-based conditioning in poor risk patients with hematologic malignancies relapsing after a previous autologous or allogeneic HSC transplant.
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Patients and methods
Patient eligibility
Patients were eligible if they had an advanced hematological malignancy and had relapsed after a previous autologous or allogeneic HSC transplant. Patients entered were not considered good candidates for total body irradiation (TBI) due to underlying pulmonary dysfunction (forced expiratory volume (FEV1), forced vital capacity (FVC), or diffusion capacity (DLCO) Ͻ50% of predicted) or cardiac dysfunction (left ventricular ejection fraction Ͻ50%), or if they had previously received irradiation with the first HSC transplant. The protocol was approved by the Institutional Review Board of the University of Illinois at Chicago (UIC), and all patients and donors provided written informed consent.
Patient characteristics
Between June 1997 and March 2000, 11 consecutive patients were enrolled. Patient and donor characteristics are summarized in Table 1 . The median patient age was 41 years (range 22-58). Nine patients had AML, one ALL, and one Hodgkin's disease (HD). Seven patients relapsed following an autologous HSC transplant and four after an HLA-identical sibling HSC transplant. The median time to relapse following the first transplant was 163 days (range 54-1886). The median interval between first and second transplants was 258 days (range 75-2065). At the time of second transplant, only one of the 11 patients was in a complete remission. Seven patients received HSC from an HLA-identical sibling and four from a relative mismatched at three HLA loci.
Pretransplant conditioning and supportive care
Conditioning for recipients of HLA-identical HSC consisted of fludarabine (25 mg/m 2 intravenously (i.v.) daily daily from days Ϫ4 to days Ϫ1). All patients received GVHD prophylaxis consisting of tacrolimus at 0.03 mg/kg/day by continuous i.v. infusion beginning on day Ϫ2. Methotrexate was administered at 5 mg/m 2 i.v. on days +1, +3, and +6 post transplant. Patients were converted to oral tacrolimus when tolerated. Tacrolimus was continued until day +180 and then tapered if there was no evidence of active GVHD. All patients received hematopoietic growth factors following HSC transplantation. Recipients of HLAidentical HSC received granulocyte colony-stimulating factor (G-CSF, Neupogen; Amgen, Thousand Oaks, CA, USA) at 5 g/kg/day subcutaneously beginning on day +7. Recipients of HLA-mismatched HSC received granulocyte-macrophage colony-stimulating factor (GM-CSF, Leukine; Immunex, Seattle, WA, USA) at 250 g/m 2 subcutaneously daily beginning on day +7. Hematopoietic growth factors were continued until the absolute neutrophil count (ANC) was greater than 1500/l for 3 consecutive days.
All patients received bacterial prophylaxis with levofloxacin at 500 mg/day orally from the beginning of conditioning until myeloid engraftment. Fungal prophylaxis consisted of fluconazole at 200 mg/day orally or i.v. to day +90 post transplant. Prophylaxis against herpes viruses consisted of acyclovir at 5 mg/kg/day every 8 h intravenously or 800 mg orally twice daily to day +180 post transplant. Pneumocystis carinii prophylaxis consisted of trimethoprim/sulfamethoxazole one double strength tablet orally twice daily on Mondays and Thursdays, beginning once patients had engrafted. Recipients of HLA-mismatched HSC received cytomegalovirus (CMV) prophylaxis using ganciclovir as previously described. 18 Recipients of HLA-identical HSC received ganciclovir at 5 mg/kg intravenously every 12 h for 2 weeks only if CMV viremia was detected by polymerase chain reaction (PCR) of white blood cells as previously described. + cells/kg recipient weight. The donor blood volume was processed three times during each leukapheresis procedure. The leukapheresis products collected from HLA-identical donors were immediately cryopreserved in 10% dimethyl sulfoxide (DMSO). Leukapheresis products collected from HLA-mismatched donors underwent CD34 + cell selection using the Nexell Isolex 300i device (version 1.12) (Nexell, Irvine, CA, USA) as previously described, in order to passively remove T lymphocytes. 20, 21 The CD34 + and CD3 + cell contents of the positively selected products were enumerated and normalized to recipient weight. The target CD34 
Hematopoietic engraftment
Myeloid engraftment was defined as achievement of an ANC of greater than 500/l on 3 consecutive days. Platelet engraftment was defined as achievement of an unsupported platelet count of greater than 20 000/l. Donor/recipient chimerism was assessed in post-transplant bone marrow samples using microsatellite probes as described below.
Graft-versus-host disease and regimen-related toxicity (RRT)
Acute and chronic GVHD were graded according to standard criteria. 22, 23 All non-hematological toxicities, including multi-organ dysfunction occurring from day 0 to day +100 were considered as regimen-related toxicity (RRT) according to the criteria of Bearman et al. 24 Adverse events related to culture documented infections were not scored as RRT.
Analysis of chimerism
Bone marrow and/or peripheral blood specimens were collected at various times following transplant for analysis of chimerism. Donor and recipient cells were detected by
Bone Marrow Transplantation quantitative analysis of informative microsatellite DNA sequences as previously described. 25 
Disease response criteria
A complete remission (CR) was defined as the absence of morphologic and radiographic evidence of disease together with normalization of peripheral blood counts. For ALL and AML, relapse was defined by standard morphologic criteria, conventional cytogenetic analysis, or both. Cytogenetic relapse was documented by the presence and persistence in more than two consecutive tests of the cytogenetic abnormality that defined the disease. For HD, relapse was defined by progression of mass(es) by radiographic criteria.
Statistical evaluation
Survival was measured from the day of transplant according to the methods of Kaplan and Meier. 26 
Results
Engraftment and chimerism
The median number of CD34 + cells transplanted was 5.3 × /kg). One recipient of HLA-mismatched HSC was not evaluable for engraftment due to early death. In the remaining 10, the median time to achieve an ANC greater than 500/l was 14 days (range 10 to 17) and to platelets greater than 20 000/l was 19 days (range 15 to 27). Eight engrafted patients, including three recipients of HLA-mismatched HSC, had 100% donor chimerism confirmed in all studies performed between days 30 and 393 post transplant. In one patient, a day +19 bone marrow sample revealed 94% donor chimerism, but on morphological examination there was evidence of persistent AML. In another patient, mixed chimerism developed just prior to clinical relapse of her AML on day +125. An additional patient with initial myeloid and platelet engraftment did not have donor chimerism studies performed.
Regimen-related toxicity
Two patients developed grade 3 RRT (Table 2) . Both patients developed grade 3 nephrotoxicity and required hemodialysis (HD). In one of these patients, thrombotic thrombocytopenic purpura (TTP) developed while on tacrolimus and required plasma exchange in addition to HD. Nine patients experienced grade 2 mucositis and required parenteral narcotic analgesics for a short period.
Acute and chronic GVHD
One patient was not evaluable for acute GVHD due to death prior to engraftment. Two of 10 evaluable patients (20%) developed grade 2-4 acute GVHD. One of these, a recipient of haploidentical HSC, had developed TTP while on tacrolimus. TTP is a well-described complication associated with the use of this immunosuppressive agent. 27 Grade 4 acute GVHD involving the skin and gut developed shortly following discontinuation of tacrolimus. The other patient had skin involvement only. In both patients, acute GVHD resolved following corticosteroids. Seven patients surviving past 100 days were evaluable for chronic GVHD. Four of these (57%) developed extensive chronic GVHD, requiring systemic immunosuppression which resulted in improvement of the GVHD in all four cases (Table 2) .
Response to treatment and relapse
One patient was not evaluable for response and relapse due to early death. Another patient with refractory AML had persistent disease detected on a bone marrow examination performed on day +19 and succumbed to his disease on day +38. A third patient with AML was in remission at the time of second transplant. Six patients achieved a CR by day +30. Two additional patients experienced morphologic clearance of disease in the bone marrow, but did not achieve normalization of peripheral blood counts. Four patients relapsed a median of 113 days (range 55-389) following transplant and all eventually died as a result ( Table 2 ).
Causes of death
The 100-day mortality from all causes was 36%. Ten of 11 patients (91%) died a median of 140 days after the second transplant (range 9-996). The causes of death included refractory or relapsed disease in five, sepsis syndrome in four, and idiopathic pneumonia syndrome (IPS) in one ( Table 2) . Two patients, both in CR, died from sepsis at 155 and 187 days, respectively, post transplant. Both had active chronic GVHD requiring treatment at the time. An additional patient was in CR without evidence of GVHD at the time of her death from IPS on day +187. RRT = regimen-related toxicity; GVHD = graft-versus-host disease; CR = complete remission; NR = no response; NE = not evaluable; CNS = central nervous system; IPS = idiopathic pneumonia syndrome; VRE = vancomycin resistant enterococcus. a Denotes toxicity grade as defined by Bearman et al. 24 
Survival
One patient with AML survives in CR at 880 days following the second transplant. The overall survival probability at 1 year was 0.18 (90% CI 0-0.41) (Figure 1 ).
Discussion
The results of this study indicate that fludarabine-and melphalan-based conditioning is relatively well tolerated as a second transplant regimen in a poor risk group of patients with active malignancy at the time of transplant. Approximately two-thirds of the patients survived the first 100 days of transplantation. Unfortunately, a high rate of relapse and late post-transplant complications continue to limit the likelihood of a favorable outcome in such patients.
Early mortality was controlled due to the relative lack of severe extramedullary toxicity associated with this regimen, combined with the use of peripheral blood-derived HSC. This observation is in line with previous studies suggesting lower early mortality in patients with advanced disease using peripheral blood in comparison to bone marrow. Multilineage hematopoietic engraftment was prompt despite the use of methotrexate for GVHD prophylaxis. Interestingly, this regimen was capable of promoting full donor chimerism in all three evaluable recipients of HLAmismatched HSC. These results are encouraging and suggest that TBI may not be an essential component of conditioning for recipients of HLA-mismatched transplants. It is unclear if the high doses of antithymocyte globulin we used in combination with fludarabine and melphalan were necessary to ensure engraftment in these patients. Whether the capacity for this regimen to promote full donor chimerism in this setting is due primarily to immunosuppression, myeloablation, or an effective combination of the two is unknown at this time. Further studies in this subset of patients appear warranted.
We were encouraged by the relative lack of toxicity in this group of heavily pretreated patients. The extramedullary toxicity appears to be primarily mucosal and renal, although one of the patients who required hemodialysis had previously developed TTP. It is also possible that the combination of tacrolimus and methotrexate used for GVHD prophylaxis contributed to the mucosal and renal toxicity. 30 Despite the early establishment of full donor chimerism, relapse rates were high. This is likely related to the refractory nature of disease in most of our patients, given the early time to relapse following the first transplant procedure. [6] [7] [8] 31 This low intensity conditioning regimen by itself, while having some antileukemic activity, is unlikely to sustain a remission in patients with advanced AML, as has been suggested previously by de Lima et al. 31 Others have also suggested that employing a less intensive pretransplant conditioning may increase the risk of relapse in patients with AML. 32 Four of the five patients who suffered relapse never developed acute or chronic GVHD prior to the onset of relapse. In contrast, three of the four patients who maintained remission for at least 5 months following transplant developed chronic GVHD. These data suggest that tapering of GVHD prophylaxis in patients who do not develop or do not have active acute GVHD should be contemplated early post transplant. A previous study suggests the feasibility of this approach following bone marrow transplantation. 33 In this context, the fludarabine-and melphalanbased regimen may provide a useful platform for immunomodulation using DLI prophylactically in such high risk patients, prior to the development of morphological relapse. However, it should be noted that sepsis caused the deaths of two of our patients in remission who were being treated actively for extensive chronic GVHD. Such patients are often frail and highly susceptible to infectious morbidity and mortality. The successful application of post transplant immunomodulation with donor leukocytes in this setting will likely require strategies aimed at genetic modification of T cells with suicide genes or the culture and expansion of leukemia-specific T cells and/or NK cells in order to avoid the numerous complications associated with GVHD. [34] [35] [36] In summary, although only one of 11 patients survived, we are encouraged by a number of properties of this conditioning regimen including: (1) relative lack of extramedullary toxicity observed in heavily pretreated patients; (2) Bone Marrow Transplantation the capacity to promote full donor chimerism in the HLAmismatched setting; (3) rapid cytoreductive ability, providing a platform for DLI; and (4) apparent low risk of acute GVHD. Nevertheless, it is clear that the vast majority of patients with refractory hematological malignancies will not benefit exclusively from this conditioning regimen.
